Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress ACCESSWIRE Advancing Dyadic 's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development and manufacture of vaccines and therapeutics Goal of bringing larger quantities of lower cost COVID-19 vaccines that can be used as a prime and booster to existing vaccines Engaged CR2O to manage and support further preclinical and c...
Source: tennesseedaily.com